Sangamo Therapeutics
Richmond
About Sangamo Therapeutics
Sangamo Therapeutics is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $50K – $100K
- Total funding: $594.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2026)
- Ticker: nasdaq:SGMO
- Website: sangamo.com
- Phone: 5102368951
Industries & Categories
Biotechnology, Genetics, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/sangamo-therapeutics-144569 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.